Table 3.
Association between interleukin polymorphisms and colorectal adenoma recurrence in participants of the Polyp Prevention Trial at the end of Year 4 (n = 808)
| Interleukin | Adenoma Recurrence |
||||||
|---|---|---|---|---|---|---|---|
| None | Any | High Risk | Advanced | ||||
| Polymorphism | n (%) | n (%) | OR (95% CI)* | n (%) | OR (95% CI)* | n (%) | OR (95% CI)* |
| IL-1β -511 | |||||||
| C/C | 190 (59.6) | 129 (40.4) | 1.00 | 43 (13.5) | 1.00 | 19 (6.0) | 1.00 |
| C/T | 222 (61.8) | 137 (38.2) | 0.90 (0.66–1.24) | 32 (8.8) | 0.61 (0.36–1.01) | 18 (5.0) | 0.76 (0.38–1.52) |
| T/T | 50 (61.1) | 28 (35.9) | 0.83 (0.49–1.41) | 8 (10.3) | 0.68 (0.29–1.57) | 4 (5.1) | 0.75 (0.24–2.36) |
| C/T + T/T | 272 (62.2) | 165 (37.8) | 0.89 (0.66–1.21) | 40 (9.2) | 0.62 (0.38–1.01) | 22 (5.0) | 0.76 (0.39–1.47) |
| P-trend | 0.42 | 0.11 | 0.46 | ||||
| IL-6 -174 | |||||||
| G/G | 181 (63.7) | 103 (36.3) | 1.00 | 30 (10.6) | 1.00 | 13 (4.6) | 1.00 |
| G/C | 208 (58.9) | 145 (41.1) | 1.25 (0.89–1.75) | 45 (12.7) | 1.40 (0.82–2.40) | 22 (6.2) | 1.76 (0.81–3.86) |
| C/C | 64 (61.0) | 41 (39.0) | 1.19 (0.74–1.91) | 9 (8.6) | 1.04 (0.45–2.40) | 8 (7.6) | 2.44 (0.89–6.64) |
| G/C + C/C | 272 (59.4) | 186 (40.6) | 1.24 (0.90–1.71) | 54 (11.8) | 1.33 (0.79–2.24) | 30 (6.6) | 1.89 (0.89–4.01) |
| P-trend | 0.32 | 0.58 | 0.07 | ||||
| IL-8 -251 | |||||||
| T/T | 118 (63.1) | 69 (36.9) | 1.00 | 16 (8.6) | 1.00 | 8 (4.3) | 1.00 |
| A/T | 228 (60.3) | 150 (39.7) | 1.16 (0.80–1.68) | 44 (11.6) | 1.45 (0.77–2.71) | 23 (6.1) | 1.50 (0.64–3.48) |
| A/A | 112 (62.6) | 67 (37.4) | 1.03 (0.66–1.60) | 16 (8.9) | 1.08 (0.50–2.33) | 10 (5.6) | 1.28 (0.47–3.49) |
| A/T + A/A | 340 (61.0) | 217 (39.0) | 1.12 (0.79–1.60) | 60 (10.8) | 1.34 (0.73–2.45) | 33 (5.9) | 1.43 (0.63–3.24) |
| P-trend | 0.87 | 0.82 | 0.63 | ||||
| IL-10 -592 | |||||||
| C/C | 264 (61.6) | 168 (38.9) | 1.00 | 51 (11.8) | 1.00 | 27 (6.3) | 1.00 |
| C/A | 171 (62.2) | 104 (37.8) | 0.92 (0.67–1.26) | 26 (9.5) | 0.76 (0.45–1.28) | 13 (4.7) | 0.69 (0.34–1.40) |
| A/A | 33 (53.2) | 29 (46.8) | 1.45 (0.83–2.53) | 7 (11.3) | 1.17 (0.47–2.90) | 3 (4.8) | 0.85 (0.23–3.08) |
| C/A + A/A | 204 (60.5) | 133 (39.5) | 0.99 (0.74–1.34) | 33 (9.8) | 0.82 (0.50–1.33) | 16 (4.7) | 0.72 (0.37–1.39) |
| P-trend | 0.55 | 0.68 | 0.42 | ||||
| IL-10 -819 | |||||||
| C/C | 267 (60.1) | 177 (39.9) | 1.00 | 54 (12.2) | 1.00 | 29 (6.5) | 1.00 |
| C/T | 173 (62.0) | 106 (38.0) | 0.90 (0.66–1.23) | 26 (9.3) | 0.72 (0.43–1.21) | 12 (4.3) | 0.60 (0.29–1.22) |
| T/T | 36 (54.5) | 30 (45.5) | 1.35 (0.79–2.33) | 17 (10.6) | 1.08 (0.44–2.67) | 3 (4.5) | 0.76 (0.21–2.76) |
| C/T + T/T | 209 (60.6) | 136 (39.4) | 0.97 (0.72–1.30) | 33 (9.6) | 0.78 (0.48–1.26) | 15 (4.3) | 0.62 (0.32–1.21) |
| P-trend | 0.70 | 0.52 | 0.24 | ||||
| IL-10 -1082 | |||||||
| A/A | 132 (59.7) | 89 (40.3) | 1.00 | 23 (10.4) | 1.00 | 11 (5.0) | 1.00 |
| A/G | 251 (61.4) | 158 (38.6) | 0.93 (0.66–1.31) | 43 (10.5) | 0.99 (0.57–1.74) | 24 (5.9) | 1.20 (0.56–2.56) |
| G/G | 88 (59.9) | 59 (40.1) | 1.06 (0.68–1.63) | 19 (12.9) | 1.36 (0.69–2.69) | 3 (4.5) | 1.21 (0.46–3.17) |
| A/G + G/G | 339 (61.0) | 217 (39.0) | 0.96 (0.70–1.34) | 62 (11.2) | 1.08 (0.64–1.84) | 15 (4.3) | 1.20 (0.58–2.49) |
| P-trend | 0.87 | 0.42 | 0.67 | ||||
| IL-10 Haplotypea | |||||||
| A-C-C | 85 (59.4) | 58 (40.6) | 1.00 | 19 (13.3) | 1.00 | 8 (5.6) | 1.00 |
| G-C-C | 161 (59.9) | 108 (40.1) | 0.93 (0.61–1.42) | 30 (11.2) | 0.76 (0.40–1.45) | 18 (6.7) | 1.14 (0.47–2.75) |
| G-T-A | 197 (61.2) | 125 (38.8) | 0.86 (0.57–1.30) | 32 (9.9) | 0.66 (0.35–1.26) | 15 (4.7) | 0.72 (0.29–1.79) |
*
All comparisons against the no adenoma group. Multivariate OR and 95% CI models were adjusted for age tertiles (<58, 58–66, >66 yrs), sex, and race (Caucasian or not). Homozygous carriers of the more frequent gene are the reference group. The dominant model is evaluated by the OR (95% CI) for carriers of the less frequent gene combined. The co-dominant model is evaluated by P-trend
a
Composed of 3 polymorphic sites: -1082 AA/G, -819 CC/T, and -592 CC/A.